ConductScience.org, home

Paper41501787

HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling.

Sun S and 14 others. Cell Commun Signal, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling. Papers, record 41501787. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41501787

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
HVEM costimulatory domain boosts CAR T cell efficacy against solid tumors via enhanced TRAF-mediated TNF signaling.
PubMed
Journal
Cell Commun Signal
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-06-25
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sun SShishuo
2Zhao WWanxin
3Liang YYibing
4Xue YYing
5Li QQihong
6Yuan YYifan
7Wang ZZhenyu
8Gao XXiaoge
9Yao YYizhou
10Xu HHaiheng
11Li HHailong
12Liu XXiaoxiao
13Tang PMPatrick Ming-Kuen
14Zheng JJunnian
15Zhang QQing

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Signal TransductionMajor topic
Receptors, Tumor Necrosis Factor, Member 14Major topic
Tumor Necrosis Factor Receptor-Associated Peptides and ProteinsMajor topic
T-LymphocytesMajor topic
Tumor Necrosis Factor-alphaMajor topic
NeoplasmsMajor topic
Receptors, Chimeric AntigenMajor topic
Animals
Humans
Mice
Cell Line, Tumor
Protein Domains

Source PubMed

Download CSV of topics

Grants9

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
KC23056Xuzhou Science and Technology Bureau projectsPubMed
82303761National Natural Science Foundation of ChinaPubMed
81972242National Natural Science Foundation of ChinaPubMed
82473333National Natural Science Foundation of ChinaPubMed
20KJA320006Natural Science Key Project of Jiangsu Provincial Education DepartmentPubMed
CXZX202234Jiangsu Provincial Key Medical Discipline, The Project of Invigorating Health Care through Science, Technology and EducationPubMed
BE2023689Jiangsu Province Social Development ProjectsPubMed
LCZX202501Construction Project of High Level Hospital of Jiangsu ProvincePubMed
QL-YB032XZHMU-QL Joint Research FundPubMed

Source PubMed

Download CSV of grants

References46

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137058548Metabolic challenges and interventions in CAR T cell therapy.Sci Immunol2023https://conductscience.org/library/papers/37058548PubMed
236350984Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies.Sci Transl Med2022https://conductscience.org/library/papers/36350984PubMed
39744859Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death.Genes Dev1998https://conductscience.org/library/papers/9744859PubMed
436689620Herpes Virus Entry Mediator Costimulation Signaling Enhances CAR T-cell Efficacy Against Solid Tumors Through Metabolic Reprogramming.Cancer Immunol Res2023https://conductscience.org/library/papers/36689620PubMed
530272343Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.Oncol Rep2018https://conductscience.org/library/papers/30272343PubMed
634230645A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.Nat Rev Clin Oncol2021https://conductscience.org/library/papers/34230645PubMed
738987856Fueling CARs: metabolic strategies to enhance CAR T-cell therapy.Exp Hematol Oncol2024https://conductscience.org/library/papers/38987856PubMed
833374128Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy.Cells2020https://conductscience.org/library/papers/33374128PubMed
926885860Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.Immunity2016https://conductscience.org/library/papers/26885860PubMed
1037516527T cell activation and effector function in the human Jurkat T cell model.Methods Cell Biol2023https://conductscience.org/library/papers/37516527PubMed
1140344863ERK1/2-MAPK signaling: Metabolic, organellar, and cytoskeletal interactions.Curr Opin Cell Biol2025https://conductscience.org/library/papers/40344863PubMed
1238821074
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Lancet Oncol2024https://conductscience.org/library/papers/38821074PubMed
1331758531The TNF-TNFR Family of Co-signal Molecules.Adv Exp Med Biol2019https://conductscience.org/library/papers/31758531PubMed
1415120041Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.Eur J Cancer2004https://conductscience.org/library/papers/15120041PubMed
1535007698Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy.Cancer Lett2022https://conductscience.org/library/papers/35007698PubMed
1638468828CAR-T Cell Therapy for T-Cell Malignancies.Mediterr J Hematol Infect Dis2024https://conductscience.org/library/papers/38468828PubMed
1736209106The journey of CAR-T therapy in hematological malignancies.Mol Cancer2022https://conductscience.org/library/papers/36209106PubMed
1838831106The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.Nat Immunol2024https://conductscience.org/library/papers/38831106PubMed
1939032532Molecular mechanism of co-stimulatory domains in promoting CAR-T cell anti-tumor efficacy.Biochem Pharmacol2024https://conductscience.org/library/papers/39032532PubMed
2021660053Expanding TRAF function: TRAF3 as a tri-faced immune regulator.Nat Rev Immunol2011https://conductscience.org/library/papers/21660053PubMed

See all 46 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42924291Universal CAR-T cell therapy: overcoming key hurdles on the path to off-the-shelf adoption.Med Rev (2021)2026https://conductscience.org/library/papers/42924291PubMed
42089445Enhancing CAR-T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF-Mediated Angiogenesis.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42089445PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41501787

GET https://conductscience.org/api/papers/v1/41501787/references?page=2